Inadvertent relaxation of the ductus arteriosus by pharmacologic agents that are commonly used in the neonatal period

Seminars in Perinatology

Volumn 34, Issue 3, 2010, Pages 222-230

  Reese, Jeff ^a,b   Veldman, Alex ^c   Shah, Lisa ^d   Vucovich, Megan ^a   Cotton, Robert B ^a  

^a MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MONASH MEDICAL CENTRE   (Australia)

^d SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aminoglycoside; Cimetidine; Ductus arteriosus; Gentamicin; Heparin; Vasodilator

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CIMETIDINE; COUMARIN DERIVATIVE; FAMOTIDINE; FUROSEMIDE; GENTAMICIN; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN DERIVATIVE; TISSUE PLASMINOGEN ACTIVATOR;

ANTIHYPERTENSIVE ACTIVITY; CLINICAL TRIAL; DRUG CLEARANCE; DRUG METABOLISM; DRUG POTENTIATION; DUCTUS ARTERIOSUS; HUMAN; LUNG INJURY; NEWBORN PERIOD; NONHUMAN; PATENT DUCTUS ARTERIOSUS; PREMATURITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR;

ANIMALS; CIMETIDINE; DUCTUS ARTERIOSUS; DUCTUS ARTERIOSUS, PATENT; GENTAMICINS; HEPARIN; HISTAMINE H2 ANTAGONISTS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; NITRIC OXIDE; PROSTAGLANDINS; RISK FACTORS; VASODILATION; VASODILATOR AGENTS;

EID: 77953112538     PISSN: 01460005     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semperi.2010.02.007     Document Type: Review

References (93)

1. Coceani F., Olley P.M. The response of the ductus arteriosus to prostaglandins. Can J Physiol Pharmacol 1973, 51:220-225.
2. Kajino H., Taniguchi T., Fujieda K., et al. An EP4 receptor agonist prevents indomethacin-induced closure of rat ductus arteriosus in vivo. Pediatr Rev 2004, 56:586-590.
3. Momma K., Toyoshima K., Takeuchi D., et al. In vivo reopening of the neonatal ductus arteriosus by a prostanoid EP4-receptor agonist in the rat. Prostaglandins Other Lipid Mediat 2005, 78:117-128.
4. Leonhardt A., Glaser A., Wegmann M., et al. Expression of prostanoid receptors in human ductus arteriosus. Br J Pharmacol 2003, 138:655-659.
5. Gonzalez A., Sosenko I.R., Chandar J., et al. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. J Pediatr 1996, 128:470-478.
6. Rojas M.A., Gonzalez A., Bancalari E., et al. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 1995, 126:605-610.
7. Friedman Z., Demers L.M., Marks K.H., et al. Urinary excretion of prostaglandin E following the administration of furosemide and indomethacin to sick low-birth-weight infants. J Pediatr 1978, 93:512-515.
8. Green T.P., Thompson T.R., Johnson D.E., et al. Furosemide promotes patent ductus arteriosus in premature infants with the respiratory-distress syndrome. N Engl J Med 1983, 308:743-748.
9. Arcilla R.A., Thilenius O.G., Ranniger K. Congestive heart failure from suspected ductal closure in utero. J Pediatr 1969, 75:74-78.
10. Friedman W.F., Hirschklau M.J., Printz M.P., et al. Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med 1976, 295:526-529.
11. Heymann M.A., Rudolph A.M., Silverman N.H. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med 1976, 295:530-533.
12. Moise K.J. Effect of advancing gestational age on the frequency of fetal ductal constriction in association with maternal indomethacin use. Am J Obstet Gynecol 1993, 168:1350-1353.
13. Norton M.E., Merrill J., Cooper B.A., et al. Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med 1993, 329:1602-1607.
14. Hammerman C., Glaser J., Kaplan M., et al. Indomethacin tocolysis increases postnatal patent ductus arteriosus severity. Pediatrics 1998, 102:E56.
15. Clyman R.I., Chen Y.Q., Chemtob S., et al. In utero remodeling of the fetal lamb ductus arteriosus: The role of antenatal indomethacin and avascular zone thickness on vasa vasorum proliferation, neointima formation, and cell death. Circulation 2001, 103:1806-1812.
16. 2-regulated ductus arteriosus contractile pathways and prevents postnatal closure. Pediatr Review 2009, 66:155-161.
17. Sodini D., Baragatti B., Barogi S., et al. Indomethacin promotes nitric oxide function in the ductus arteriosus in the mouse. Br J Pharmacol 2008, 153:1631-1640.
18. Momma K., Toyono M. The role of nitric oxide in dilating the fetal ductus arteriosus in rats. Pediatr Review 1999, 46:311-315.
19. Richard C., Gao J., LaFleur B., et al. Patency of the preterm fetal ductus arteriosus is regulated by endothelial nitric oxide synthase and is independent of Vasa vasorum in the mouse. Am J Physiol Regul Integr Comp Physiol 2004, 287:R652-R660.
20. Keller R.L., Tacy T.A., Fields S., et al. Combined treatment with a nonselective nitric oxide synthase inhibitor (l-NMMA) and indomethacin increases ductus constriction in extremely premature newborns. Pediatr Rev 2005, 58:1216-1221.
21. Reese J., O'Mara P.W., Poole S.D., et al. Regulation of the fetal mouse ductus arteriosus is dependent on interaction of nitric oxide and COX enzymes in the ductal wall. Prostaglandins Other Lipid Mediat 2009, 88:89-96.
22. Kinsella J.P., Walsh W.F., Bose C.L., et al. Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: A randomised controlled trial. Lancet 1999, 354:1061-1065.
23. Schreiber M.D., Gin-Mestan K., Marks J.D., et al. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 2003, 349:2099-2107.
24. Mentzer R.M., Ely S.W., Lasley R.D., et al. Hormonal role of adenosine in maintaining patency of the ductus arteriosus in fetal lambs. Ann Surg 1985, 202:223-230.
25. Smith G.C., McGrath J.C. Characterisation of the effect of oxygen tension on response of fetal rabbit ductus arteriosus to vasodilators. Cardiovasc Res 1993, 27:2205-2211.
26. Toyoshima K., Momma K., Imamura S., et al. In vivo dilatation of the postnatal ductus arteriosus by atrial natriuretic peptide in the rat. J Neonatol 2007, 92:139-144.
27. Liu H., Manganiello V., Waleh N., et al. Expression, activity, and function of phosphodiesterases in the mature and immature ductus arteriosus. Pediatr Rev 2008, 64:477-481.
28. Thebaud B., Michelakis E., Wu X.C., et al. Sildenafil reverses O2 constriction of the rabbit ductus arteriosus by inhibiting type 5 phosphodiesterase and activating BK(Ca) channels. Pediatr Rev 2002, 52:19-24.
29. Arishima K., Takizawa T., Oda T., et al. Propranolol inhibits the spontaneous closure of the ductus arteriosus in newborn rats. J Vet Med Sci 1995, 57:943-944.
30. Friedman W.F., Printz M.P., Kirkpatrick S.E., et al. The vasoactivity of the fetal lamb ductus arteriosus studied in utero. Pediatr Rev 1983, 17:331-337.
31. Clyman R.I., Roman C. The effects of caffeine on the preterm sheep ductus arteriosus. Pediatr Rev 2007, 62:167-169.
32. del Moral T., Gonzalez-Quintero V.H., Claure N., et al. Antenatal exposure to magnesium sulfate and the incidence of patent ductus arteriosus in extremely low birthweight infants. J Perinatol 2007, 27:154-157.
33. Stigson L., Kjellmer I. Serum levels of magnesium at birth related to complications of immaturity. Acta Paediatr 1997, 86:991-994.
34. McGuirl J, Arzuaga B, Lee B: Increased risk for patent ductus arteriosus with antenatal calcium channel blocker exposure in extremely low birthweight infants. Annual Meeting of the Pediatric Academic Societies. EPAS 461, 2009 (abstr).
35. Watterberg K.L., Kelly H.W., Johnson J.D., et al. Effect of patent ductus arteriosus on gentamicin pharmacokinetics in very low birthweight (less than 1,500 g) babies. Dev Pharmacol Ther 1987, 10:107-117.
36. Adams H.R., Goodman F.R., Weiss G.B. Alteration of contractile function and calcium ion movements in vascular smooth muscle by gentamicin and other aminoglycoside antibiotics. Antimicrob Agents Chemother 1974, 5:640-646.
37. Belus A., White E. Effects of antibiotics on the contractility and Ca2+ transients of rat cardiac myocytes. Eur J Pharmacol 2001, 412:121-126.
38. Descotes J., Evreux J.C. Cardiac depressant effects of some recent aminoglycoside antibiotics. J Antimicrob Chemother 1981, 7:197-200.
39. Gotanda K., Yanagisawa T., Satoh K., et al. Are the cardiovascular effects of gentamicin similar to those of calcium antagonists?. Jpn J Pharmacol 1988, 47:217-227.
40. Coceani F., Liu Y., Seidlitz E., et al. Endothelin A receptor is necessary for O(2) constriction but not closure of ductus arteriosus. Am J Physiol 1999, 277:H1521-H1531.
41. Gergawy M., Vollrath B., Cook D. The mechanism by which aminoglycoside antibiotics cause vasodilation of canine cerebral arteries. Br J Pharmacol 1998, 125:1150-1157.
42. Keith R.A., Mangano T.J., Defeo P.A., et al. Actions of neomycin on neuronal L-, N-, and non-L/non-N-type voltage-sensitive calcium channel responses. J Mol Neurosci 1992, 3:147-154.
43. Martinez C., Albet C., Agundez J.A., et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther 1999, 65:369-376.
44. Rendic S., Kajfez F., Ruf H.H. Characterization of cimetidine, ranitidine, and related structures' interaction with cytochrome P-450. Drug Metab Dispos Biol Fate Chem 1983, 11:137-142.
45. Levine M., Bellward G.D. Effect of cimetidine on hepatic cytochrome P450: Evidence for formation of a metabolite-intermediate complex. Drug Metab Dispos Biol Fate Chem 1995, 23:1407-1411.
46. Hazinski T.A., France M., Kennedy K.A., et al. Cimetidine reduces hyperoxic lung injury in lambs. J Appl Physiol 1989, 67:2586-2592.
47. Cotton R.B., Hazinski T.A., Morrow J.D., et al. Cimetidine does not prevent lung injury in newborn premature infants. Pediatr Review 2006, 59:795-800.
48. Cotton R.B., Reese J. Symptomatic patent ductus arteriosus is significantly associated with cimetidine treatment in premature newborn infants at risk for chronic lung disease Pediatr Review, 1999. EPAS 2009, 5511:178. (abstr.).
49. Coceani F. Cytochrome P450 in the contractile tone of the ductus arteriosus: Regulatory and effector mechanisms. The Fetal and Neonatal Pulmonary Circulations 1999, 331-341. Futura Publishing, Armonk, NY. E.K. Weir, S.L. Archer, J.T. Reeves (Eds.).
50. Barrington K.J. Umbilical artery catheters in the newborn: Effects of heparin. Cochrane Database System Rev 2002, (2). CD000507.
51. Shah P.S., Shah V.S. Continuous heparin infusion to prevent thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters. Cochrane Database of System Rev 2008, (2). CD002772.
52. Gilbert N.C., Nalefski L.A. The effect of heparin and dicumarol in increasing the coronary flow volume. J Lab Clin Med 1949, 34:797-805.
53. Urban P., Scheidegger D., Buchmann B., et al. The hemodynamic effects of heparin and their relation to ionized calcium levels. J Thorac Cardiovasc Surg 1986, 91:303-306.
54. Tangphao O., Chalon S., Moreno H.J., et al. Heparin-induced vasodilation in human hand veins. Clin Pharmacol Ther 1999, 66:232-238.
55. Susic D., Mandal A.K., Jovovic D., et al. Antihypertensive action of heparin: Role of the renin-angiotensin aldosterone system and prostaglandins. J Clin Pharmacol 1993, 33:342-347.
56. Tasatargil A., Golbasi I., Sadan G., et al. Unfractioned heparin produces vasodilatory action on human internal mammary artery by endothelium-dependent mechanisms. J Cardiovasc Pharmacol 2005, 45:114-119.
57. VanTeeffelen J.W., Brands J., Jansen C., et al. Heparin impairs glycocalyx barrier properties and attenuates shear dependent vasodilation in mice. Hypertension 2007, 50:261-267.
58. Ojala T.H., Lehtonen L. A preliminary report-Heparin counteracts indomethacin effect on ductus arteriosus in very low birthweight infants. Pediatr Crit Care Med 2007, 8:258-260.
59. Cotton R.B., Lindstrom D.P., Stahlman M.T. Early prediction of symptomatic patent ductus arteriosus from perinatal risk factors: A discriminant analysis model. Acta Paediatr Scand 1981, 70:723-727.
60. Furzan J.A., Reisch J., Tyson J.E., et al. Incidence and risk factors for symptomatic patent ductus arteriosus among inborn very-low-birth-weight infants. Early Hum Dev 1985, 12:39-48.
61. Chorne N., Jegatheesan P., Lin E., et al. Risk factors for persistent ductus arteriosus patency during indomethacin treatment. J Pediatr 2007, 151:629-634.
62. Itabashi K., Ohno T., Nishida H. Indomethacin responsiveness of patent ductus arteriosus and renal abnormalities in preterm infants treated with indomethacin. J Pediatr 2003, 143:203-207.
63. Siassi B., Blanco C., Cabal L.A., et al. Incidence and clinical features of patent ductus arteriosus in low-birthweight infants: A prospective analysis of 150 consecutively born infants. Pediatrics 1976, 57:347-351.
64. van de Bor M., Verloove-Vanhorick S.P., Brand R., et al. Patent ductus arteriosus in a cohort of 1338 preterm infants: A collaborative study. Paediatr Perinat Epidemiol 1988, 2:328-336.
65. Robel-Tillig E., Knupfer M., Vogtmann C. Cardiac adaptation in small for gestational age neonates after prenatal hemodynamic disturbances. Early Hum Dev 2003, 72:123-129.
66. Cunningham M.D., Ellison R.C., Zierler S., et al. Perinatal risk assessment for patent ductus arteriosus in premature infants. Obstet Gynecol 1986, 68:41-45.
67. Kreft-Jais C., Plouin P.F., Tchobroutsky C., et al. Angiotensin-converting enzyme inhibitors during pregnancy: A survey of 22 patients given captopril and nine given enalapril. Br J Obstet Gynaecol 1988, 95:420-422.
68. Shotan A., Widerhorn J., Hurst A., et al. Risks of angiotensin-converting enzyme inhibition during pregnancy: Experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 1994, 96:451-456.
69. Thomas S.V., Ajaykumar B., Sindhu K., et al. Cardiac malformations are increased in infants of mothers with epilepsy. Pediatr Cardiol 2008, 29:604-608.
70. Dusick A.M., Covert R.F., Schreiber M.D., et al. Risk of intracranial hemorrhage and other adverse outcomes after cocaine exposure in a cohort of 323 very low birthweight infants. J Pediatr 1993, 122:438-445.
71. Levy H.L., Guldberg P., Guttler F., et al. Congenital heart disease in maternal phenylketonuria: Report from the maternal PKU collaborative study. Pediatr Rev 2001, 49:636-642.
72. Rouse B., Matalon R., Koch R., et al. Maternal phenylketonuria syndrome: Congenital heart defects, microcephaly, and developmental outcomes. J Pediatr 2000, 136:57-61.
73. Treszl A., Szabo M., Dunai G., et al. Angiotensin II type 1 receptor A1166C polymorphism and prophylactic indomethacin treatment induced ductus arteriosus closure in very low birthweight neonates. Pediatr Rev 2003, 54:753-755.
74. Keller R.L., Clyman R.I. Persistent Doppler flow predicts lack of response to multiple courses of indomethacin in premature infants with recurrent patent ductus arteriosus. Pediatrics 2003, 112:583-587.
75. Cambonie G., Guillaumont S., Luc F., et al. Haemodynamic features during high-frequency oscillatory ventilation in preterms. Acta Paediatr 2003, 92:1068-1073.
76. Van Overmeire B., Smets K., Lecoutere D., et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000, 343:674-681.
77. Botto L.D., Correa A., Erickson J.D. Racial and temporal variations in the prevalence of heart defects. Pediatrics 2001, 107:E32.
78. Bell E.F., Acarregui M.J. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. Cochrane Database of System Rev 2008, (1). CD000503.
79. Hammoud M.S., Elsori H.A., Hanafi E.A., et al. Incidence and risk factors associated with the patency of ductus arteriosus in preterm infants with respiratory distress syndrome in Kuwait. Saudi Med J 2003, 24:982-985.
80. Rothman K.J., Fyler D.C. Sex, birth order, and maternal age characteristics of infants with congenital heart defects. Am J Epidemiol 1976, 104:527-534.
81. Samanek M., Voriskova M. Congenital heart disease among 815,569 children born between 1980 and 1990 and their 15-year survival: A prospective Bohemia survival study. Pediatr Cardiol 1999, 20:411-417.
82. Forsey J.T., Elmasry O.A., Martin R.P. Patent arterial duct. Orphanet J Rare Dis 2009, 4:17.
83. Bhandari V., Zhou G., Bizzarro M.J., et al. Genetic contribution to patent ductus arteriosus in the premature newborn. Pediatrics 2009, 123:669-673.
84. Dagle J.M., Lepp N.T., Cooper M.E., et al. Determination of genetic predisposition to patent ductus arteriosus in preterm infants. Pediatrics 2009, 123:1116-1123.
85. Seppanen M.P., Ojanpera O.S., Kaapa P.O., et al. Delayed postnatal adaptation of pulmonary hemodynamics in infants of diabetic mothers. J Pediatr 1997, 131:545-548.
86. Alzamora-Castro V., Battilana G., Abugattas R., et al. Patent ductus arteriosus and high altitude. Am J Cardiol 1960, 5:761-763.
87. Miao C.Y., Zuberbuhler J.S., Zuberbuhler J.R. Prevalence of congenital cardiac anomalies at high altitude. J Am Coll Cardiol 1988, 12:224-228.
88. Doyle P.E., Beral V., Botting B., et al. Congenital malformations in twins in England and Wales. J Epidemiol Community Health 1991, 45:43-48.
89. Layde P.M., Erickson J.D., Falek A., et al. Congenital malformation in twins. Am J Hum Genet 1980, 32:69-78.
90. Gibson S., Lewis K.C. Congenital heart disease following maternal rubella during pregnancy. AMA 1952, 83:317-319.
91. Nakagawa T. Delayed closure of ductus arteriosus in premature infants with transient hypothyroidism. Lancet 1993, 341:839.
92. Williams F.L., Ogston S.A., van Toor H., et al. Serum thyroid hormones in preterm infants: Associations with postnatal illnesses and drug usage. J Clin Endocrinol Metab 2005, 90:5954-5963.
93. Barefield E.S., Dwyer M.D., Cassady G. Association of patent ductus arteriosus and phototherapy in infants weighing less than 1000 grams. J Perinatol 1993, 13:376-380.